LONDON, UK / ACCESSWIRE / April 1, 2019 / Kazia Therapeutics (NASDAQ: KZIA) presented encouraging data from the Cantrixil Phase I study in a poster at American Association for Cancer Research (AACR) this week. Five of the nine evaluable patients (56%) showed stable disease at the completion of monotherapy treatment and one patient achieved an ongoing partial response to Cantrixil plus paclitaxel therapy. The extension cohort has already recruited nine of 12 subjects; data likely H219. Kazia's primary focus is on GDC-0084, which is in three clinical studies in brain cancers. Initial data from the Phase IIa study in glioblastoma are expected in Q219. We increase our valuation range to between $64m and $111m.
We increase our indicative valuation range to $64–111m or $10.31–17.82 per ADR (vs $63–105m, $10.51–17.57 per ADR), under either post-Phase III approval or accelerated approval scenarios for GDC-0084. We have rolled forward our model and have made adjustment for the sale of the Noxopharm shareholding for $1.8m (vs our previous valuation of $2.7m). We estimate that cash of $4.1m at 31 December 2018 plus the Noxopharm sale proceeds will fund activity into H219, by which time preliminary data from the GDC-0084 Phase IIa are expected to have read out. We estimate that Kazia will need additional funds in the order of $11-15m to fully fund the GDC-0084 Phase IIb study.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website www.edisongroup.com
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Dr Dennis Hulme, +61 (0)2 8249 8345
Dr Daniel Wilkinson, +44 (0)20 3077 5734
Learn more at www.edisongroup.com and connect with Edison on:
SOURCE: Edison Investment Research Limited